Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of $0.22, $0.10 better than the analyst estimate of $0.12. Revenue for the quarter came in at $264.03 million versus the consensus estimate of $227.61 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.